Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)

Trial Profile

Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Doxorubicin; Etoposide; Vincristine
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2015 Status changed from recruiting to active, no longer recruiting; according to an abstract presented at the 16th World Conference on Lung Cancer.
    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top